<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399996</url>
  </required_header>
  <id_info>
    <org_study_id>PKE PROBIOTIC</org_study_id>
    <nct_id>NCT01399996</nct_id>
  </id_info>
  <brief_title>Influence of a Delivery System on the Efficacy of a Probiotic Intervention</brief_title>
  <official_title>Influence of a Delivery System on the Efficacy of a Probiotic Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Management Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed work we will evaluate the efficacy of a probiotic bacterium (Bifidobacterium&#xD;
      animalis subsp. lactis BB12) delivered in a yogurt smoothie (organism to be added before or&#xD;
      after fermentation) or as a supplement (tablet) by assessing 1) bowel habits (transit time);&#xD;
      2) the ecology of the bacterial community in the GIT; and 3) immune status of healthy human&#xD;
      volunteers. In addition to providing information about the relative efficacy of the delivery&#xD;
      vehicles on probiotic function it will provide novel information about the influence of the&#xD;
      yogurt smoothie alone (control) on all the parameters measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics (health-promoting bacteria) are often considered &quot;functional ingredients&quot; that act&#xD;
      independently of the matrix used to deliver them to the human host. This thinking ignores the&#xD;
      impact the delivery matrix (food or dietary supplement) may have on both the physiology of&#xD;
      the probiotic organism and on the human host and is likely not true.&#xD;
&#xD;
      Historically the most common &quot;probiotic foods&quot; have been fermented dairy products,&#xD;
      particularly yogurts. Since yogurts are commonly understood to contain live &quot;good&quot; bacteria&#xD;
      they are well accepted by consumers. However, increasingly over the last decade, probiotics&#xD;
      are being added to non-dairy-based foods (juice, chocolate, cookies, etc) or consumed as&#xD;
      supplements (tablets/capsules). While this expands the options for people to obtain probiotic&#xD;
      organism, it is not clear whether probiotics delivered in these products are as efficacious&#xD;
      as when delivered in a dairy food. In fact, the buffering capacity and nutrient composition&#xD;
      of milk products may directly influence efficacy of the probiotic by increasing survival&#xD;
      during passage through the gastrointestinal tract (GIT) and by modifying the physiology of&#xD;
      the probiotic organism. In addition, fermentation products produced by the probiotic during&#xD;
      manufacture of yogurt may also have an influence on the efficacy of probiotic bacteria.&#xD;
&#xD;
      Our hypotheses are:&#xD;
&#xD;
        1. The vehicle used to deliver probiotic bacteria into the body influences the performance&#xD;
           of the probiotic in vivo. Specifically, consumption of yogurt-based smoothie containing&#xD;
           probiotic bacteria will result in greater decrease in fecal transit time, and have a&#xD;
           greater effect on the composition of the fecal microbiota and on markers of immune&#xD;
           status than the same probiotic bacteria delivered at the same level in the form of a&#xD;
           dietary supplement (tablet).&#xD;
&#xD;
        2. Timing of the addition of probiotic organism to the yogurt smoothie (pre or post&#xD;
           fermentation) will not change the efficacy of the probiotic with respect to the outcomes&#xD;
           being assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal transit time</measure>
    <time_frame>Weeks 4, 10, 16, 22</time_frame>
    <description>Gastrointestinal transit time is the amount of time it takes for food to travel through the digestive tract to be excreted. It will be measured using the SmartPill wireless motility capsule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the fecal microbiota profile at 4 weeks following each of the 4 interventions and 1 free living period</measure>
    <time_frame>Weeks 4, 10, 16, 22 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in immune status at 4 weeks following each of the 4 interventions and 1 free living period</measure>
    <time_frame>Weeks 4, 10, 16, 22, 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Delayed Transit Time</condition>
  <condition>Irregular Bowel Function</condition>
  <arm_group>
    <arm_group_label>Yogurt smoothie without probiotic.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic added post fermentation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic added pre-fermentation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A capsule containing the probiotic.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt smoothie without probiotic</intervention_name>
    <description>A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).</description>
    <arm_group_label>Yogurt smoothie without probiotic.</arm_group_label>
    <other_name>Yogurt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt smoothie with probiotic added post fermentation</intervention_name>
    <description>A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).</description>
    <arm_group_label>Probiotic added post fermentation.</arm_group_label>
    <other_name>Yogurt with probiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt smoothie with probiotic added pre-fermentation</intervention_name>
    <description>A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).</description>
    <arm_group_label>Probiotic added pre-fermentation.</arm_group_label>
    <other_name>Yogurt with probiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A capsule containing the probiotic</intervention_name>
    <description>A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).</description>
    <arm_group_label>A capsule containing the probiotic.</arm_group_label>
    <other_name>Probiotic capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  18-40 years of age&#xD;
&#xD;
          -  Body mass index between 20 and 35 kg/m^2&#xD;
&#xD;
          -  Persons with irregular bowel function as determined using the Rome III criteria (1)&#xD;
             which is used to classify functional gastrointestinal disorders.&#xD;
&#xD;
          -  Increased gastrointestinal transit time &gt; 60 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking and/or use of other tobacco products&#xD;
&#xD;
          -  Blood pressure greater than 140/90 mm Hg&#xD;
&#xD;
          -  A history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney&#xD;
             disease and thyroid disease (unless controlled by medication and blood results within&#xD;
             the previous 6 months are provided).&#xD;
&#xD;
          -  Lactation, pregnancy or desire to become pregnant during the study&#xD;
&#xD;
          -  Use of cholesterol-lowering medication&#xD;
&#xD;
          -  Refusal to discontinue intake of putative cholesterol-lowering supplements (psyllium,&#xD;
             fish oil capsules, soy lecithin, niacin, fiber, flax, phytoestrogens, stanol/sterol&#xD;
             supplemented foods&#xD;
&#xD;
          -  Refusal to discontinue probiotics,nutritional supplements, herbs or vitamins&#xD;
&#xD;
          -  Vegetarianism/Veganism&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Clinical diagnosis of Inflammatory Bowel Disease (IBD), e.g. Crohn's Disease or&#xD;
             ulcerative colitis&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt; 14 standard drinks per week)&#xD;
&#xD;
          -  Chronic use of anti-inflammatory medications (unless able to discontinue)&#xD;
&#xD;
          -  Individuals taking stool softeners or enemas on a regular basis.&#xD;
&#xD;
          -  Allergy to polyvinyl chloride (PVC) or any other type of plastic&#xD;
&#xD;
          -  Individuals with a bowel transit time of &lt; 60 hours at time of screening&#xD;
&#xD;
          -  Individuals with swallowing disorders or dysphagia to food or pills&#xD;
&#xD;
          -  Suspected strictures, fistulas, or physiological GI Obstruction&#xD;
&#xD;
          -  GI surgery within the past three months&#xD;
&#xD;
          -  Refusal to agree to give blood or plasma for the length of the study.&#xD;
&#xD;
        Note: If a participant experiences a delay in passing the capsule (beyond five days) they&#xD;
        will be treated accordingly and excluded from future participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41. Review.</citation>
    <PMID>17013448</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>microbiota</keyword>
  <keyword>transit time</keyword>
  <keyword>immunity</keyword>
  <keyword>immune function</keyword>
  <keyword>constipation</keyword>
  <keyword>bowel function</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

